Carrie Xiao focuses on Healthcare and Life Science industries strategy and operation. In the past 15 years working in the US and China healthcare industries, she has advised established and startup companies in topics covering growth strategy and operating model transformations through organic and inorganic methods.
In recent years, she helped several new entrant biopharma and med tech companies to navigate China’s regulatory landscape and define feasible market entry options. She also worked with global and China management team at leading pharma and med tech companies to evaluate the implication of changing regulatory landscape and define plans to grow under-penetrated markets, accelerate time to market and pipeline while mitigating operational risks, enhancing supply chain resilience, and managing local competition.

Carrie graduated from Wuhan University with a BA in Economics. She also holds an MBA from UCLA Anderson School of Management.

Alan heads the commercial strategy and research practice for Mainland China and has 25 years of client service experience.
His recent projects have been centered around helping MNC clients navigate the recent US-China tensions successfully through creating decision options on a series of inter-related topics. This has included advice on how to increase local autonomy of China-based executives (governance), navigate geo-political tensions and explore solutions (entity structures, joint venturing, IPO plans, local manufacturing, government regulations, etc.) and the implications of China policy and macro-environments (talent programs, IP management, etc.).

Alan holds an MBA from London Business School; he is completing his doctorate on Sino-Foreign Joint Venture Formations at Cranfield University.